Related Experiment Video
Updated: Jul 20, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response
Philip Bland1, Harry Saville1, Patty T Wai1
1The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Abstract:
SF3B1 hotspot mutations are associated with a poor prognosis in several tumor types and lead to global disruption of canonical splicing. Through synthetic lethal drug screens, we identify that SF3B1 mutant (SF3B1MUT) cells are selectively sensitive to poly (ADP-ribose) polymerase inhibitors (PARPi), independent of hotspot mutation and tumor site. SF3B1MUT cells display a defective response to PARPi-induced replication stress that occurs via downregulation of the cyclin-dependent kinase 2 interacting protein (CINP), leading to increased replication fork origin firing and loss of phosphorylated CHK1 (pCHK1; S317) induction. This results in subsequent failure to resolve DNA replication intermediates and G2/M cell cycle arrest. These defects are rescued through CINP overexpression, or further targeted by a combination of ataxia-telangiectasia mutated and PARP inhibition. In vivo, PARPi produce profound antitumor effects in multiple SF3B1MUT cancer models and eliminate distant metastases. These data provide the rationale for testing the clinical efficacy of PARPi in a biomarker-driven, homologous recombination proficient, patient population.
Insights
SF3B1 mutations predict poor outcomes, but SF3B1 mutant cells are sensitive to PARP inhibitors (PARPi). This sensitivity stems from defective DNA repair, offering a new therapeutic strategy for SF3B1-mutant cancers.
Area of Science:
- Cancer Biology
- Molecular Oncology
- Genetics
Background:
- SF3B1 hotspot mutations are linked to poor prognosis across various cancers.
- These mutations cause widespread disruption of canonical RNA splicing.
- Understanding the vulnerabilities of SF3B1-mutant cells is crucial for targeted therapies.
Purpose of the Study:
- To identify therapeutic vulnerabilities in SF3B1-mutant cancer cells.
- To investigate the mechanism underlying sensitivity to poly (ADP-ribose) polymerase inhibitors (PARPi).
- To evaluate the in vivo efficacy of PARPi in SF3B1-mutant cancer models.
Main Methods:
- Synthetic lethal drug screens were employed to identify drugs targeting SF3B1 mutant (SF3B1MUT) cells.
- Cellular responses to PARPi-induced replication stress were analyzed.
- The role of cyclin-dependent kinase 2 interacting protein (CINP) and DNA damage response pathways (CHK1, ATM) was investigated.
- In vivo studies utilized SF3B1MUT cancer models to assess PARPi efficacy.
Main Results:
- SF3B1MUT cells exhibit selective sensitivity to PARPi, irrespective of mutation site or tumor origin.
- These cells show a compromised response to PARPi-induced replication stress due to CINP downregulation.
- This leads to increased replication origin firing, reduced pCHK1 (S317) induction, and failure to arrest the cell cycle.
- CINP overexpression rescues these defects, and combination therapy with ATM and PARP inhibitors shows promise.
- PARPi demonstrated significant antitumor effects and reduced metastasis in vivo.
Conclusions:
- SF3B1 mutations create a vulnerability to PARPi by impairing DNA replication stress response.
- Targeting this vulnerability with PARPi offers a potential therapeutic strategy for SF3B1MUT cancers.
- Clinical trials of PARPi in biomarker-selected, homologous recombination proficient patients are warranted.
More Related Videos
Related Concept Videos
Long-patch Base Excision Repair
The DNA Replication Fork
Restarting Stalled Replication Forks
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
DNA Damage can Stall the Cell Cycle
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

